Skip to main content

NOW APPROVED THE FIRST AND ONLY
FDA-APPROVED
TREATMENT
FOR ADULTS WITH
BULLOUS PEMPHIGOID

DUPIXENT is indicated for the
treatment of
adult patients with
bullous pemphigoid (BP).

DUPIXENT is the only biologic that inhibits IL‑4 and IL‑13 signaling,
two of the key drivers of underlying type 2 inflammation that contribute to bullous pemphigoid.1,2

The mechanism of dupilumab action has not been definitively established.

Download Prescribing Information

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers
financial assistance for eligible patients, one-on-one nursing support, and more.

DISCOVER DUPIXENT MyWay PROGRAM BENEFITS

DUPIXENT MyWay
ENROLLMENT FORMS
English Enrollment Form

DUPIXENT IS FDA-APPROVED
IN MULTIPLE dermatologic Conditions

DUPIXENT is now indicated to treat adults with bullous pemphigoid, in addition
to other dermatologic conditions.1

Uncontrolled moderate-to-severe
atopic dermatitis
(ages 6+ months)

Chronic spontaneous urticaria
Symptomatic despite
H1 antihistamines
(ages 12+ years)
Limitations of Use:
Not indicated for
treatment
of other forms of urticaria

Prurigo nodularis
(ages 18+ years)

>1,000,000
Patients on therapy

across approved
indications worldwide3,a

aThis worldwide number is largely comprised from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, the UK, and the US), with the
rest of the world comprising ≈10% of this number. This number is comprised of the following US approved indications: AD, asthma, CRSwNP, PN, EoE, and COPD.
Data through February 2025.

QUESTIONS ABOUT
DUPIXENT?

Connect with a Field Representative to discuss questions you may have
about prescribing DUPIXENT to your patients with bullous pemphigoid.

CONTACT A REP